Replimune Group, Inc.

Healthcare

NASDAQ:REPL · NASDAQ Global Select

Market Cap $841.41M Beta 0.91 P/E (TTM) -3.0

$10.19 +1.85%

+$0.19 today

52W Low $1.50High $13.24

Vol 2.47M · Avg 7.51M

EPS (TTM) -$3.42Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+10.40%

Period High

$12.63

Period Low

$1.70

Latest

$10.19

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Vir Biotechnology, Inc.

NASDAQ:VIR

$1.53B

ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

$1.48B

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

$1.40B

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

$1.38B

MeiraGTx Holdings plc

NASDAQ:MGTX

$1.01B

Astria Therapeutics, Inc.

ATXS

$718.13M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

$575.84M

Prime Medicine, Inc.

NASDAQ:PRME

$568.04M

Valneva SE

NASDAQ:VALN

$507.30M

Arvinas, Inc.

NASDAQ:ARVN

$487.14M

What is the latest REPL filing?

The latest filing shown is 4 dated Jun 3, 2026.

How many recent filings does REPL have?

Intrinsic Alpha currently shows 20 recent filings for REPL.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.